ArticleCancer immunology, immunotherapy : CII2018
The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
David Briere et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
89 papers cite itlatest 60 shown
this paperpooled itcites it